证券之星消息，8月1日农产品加工板块较上一交易日下跌0.71%，安德利领跌。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。农产品加工板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300138 | 晨光生物 | 13.43 | 2.21% | 15.81万 | 2.13亿 | | 600962 | 国投中鲁 | 18.98 | 1.61% | 6.63万 | 1.25亿 | | 603182 | 喜华股份 | 14.31 | 1.35% | 1.92万 | 2726.61万 | | 603231 | 索宝蛋白 | 17.17 | 1.12% | 1.83万 | 3147.97万 | | 002481 | 双塔食品 | 5.35 | 0.75% | 7.36万 | 3925.01万 | | 300268 | *ST佳沃 | 10.26 | 0.69% | 1.55万 | 1592.77万 | | 001338 | 永顺泰 ...

Group 1 - The core viewpoint of the article is that the company, Morning Light Bio (300138), is focusing on the independent development of its cottonseed business to maximize overall efficiency despite its characteristics of high revenue volume, strong volatility, and low profit margins [1] Group 2 - The cottonseed business is characterized by its commodity nature, leading to significant revenue fluctuations and lower gross margins [1] - The company aims to continue promoting the independent development of its cottonseed business [1] - The strategy is intended to enhance the overall effectiveness of the company's operations [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 605198 | 安德利 | 51.81 | 8.98% | 6.15万 | | 3.07亿 | | 600191 | 一周边 | 7.72 | 0.65% | 6.09万 | 4666.43万 | | | 300138 | 晨光生物 | 13.14 | 0.00% | 7.59万 | 9999.93万 | | | 002852 | 道道全 | 12.13 | -0.16% | 21.77万 | | 2.63亿 | | 002286 | 保龄宝 | 10.53 | -0.57% | 8.74万 | 9238.66万 | | | 300175 | ST朗源 | 5.06 | -0.98% | 4.87万 | 2486.14万 | | | 600737 | 中粮糖业 | 9.79 | -1.51% | 18.32万 | | 1.80亿 | | 003030 | 祖名股份 | 19.07 | -1.55% | 1.88万 | 3620.6 ...

Group 1 - The company, Morning Light Bio, announced that it has officially obtained a patent certificate issued by the National Intellectual Property Administration [2] - The subsidiary, Hebei Morning Light Testing Technology Service Co., Ltd., has also received a software copyright registration certificate from the National Copyright Administration [2]

证券日报网讯 7月30日晚间，晨光生物发布公告称，公司及子公司无逾期对外担保情况。 （文章来源：证券日报） ...

Group 1 - The core announcement from the company is regarding the acquisition of patent certificates and software copyright registration for new products, including a soft capsule coating composition and a method for producing chili red pigment [1] - The company's revenue composition for the year 2024 is entirely from the agricultural and sideline food processing industry, specifically plant extracts, accounting for 100.0% [1] - As of the report date, the market capitalization of the company is 6.3 billion yuan [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"或"晨光生物"）于近 日正式取得了国家知识产权局颁发的专利证书；子公司——河北晨光检测技术服 务有限公司（以下简称"晨光检测"）于近日正式取得了国家版权局颁发的计算 机软件著作权登记证书，具体情况如下： 一、取得专利证书的情况 证券代码：300138 证券简称：晨光生物 公告编号：2025—070 晨光生物科技集团股份有限公司 关于取得专利证书及软件著作权登记证书的公告 （一）取得国内专利证书的情况 | 专利名称 | 专利号 | | 证书号 | | | | 授权公告日 | | 类型 | 专利 权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 一种软胶囊外裹粉组合物、 | ZL202311103083.2 | 第 | 8109644 | 号 | 2025 | 年 | 07 | 月 | | | | 软胶囊外裹层及其制备方法 | | | | | 25 日 | | | | | ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—071 晨光生物科技集团股份有限公司 关于子公司归还银行借款暨为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）对合并报表范围内子 公司银行借款担保情况因业务进展发生了变动，现公告如下： 一、对外担保基本情况及进展 结合自身经营流动资金需求，经公司 2023 年年度股东大会决议，巴州晨光 植物蛋白有限公司（以下简称"巴州蛋白"，系子公司新疆晨光生物科技股份有 限公司全资子公司，穿透后为公司控股子公司）前期向中国银行股份有限公司巴 音郭楞蒙古自治州分行（以下简称"巴州中行"）提出 10,000 万元流动资金借 款申请，经过核查，巴州中行同意了巴州蛋白的借款申请，担保方式：公司保证 担保。 公司与巴州中行就上述借款事宜签署了《保证合同》，主债权为：主合同项 下发生的债权，包括本金、利息、违约金、赔偿金、实现债权的费用、因债务人 违约而给债权人造成的损失和其他所有应付费用；保证方式为：连带责任保证； 保证期间为：主债权的清偿期届满 ...

Core Insights - The increasing prevalence of electronic devices has heightened awareness of the potential visual hazards associated with prolonged screen exposure, leading to a surge in demand for lutein as a vital nutrient for eye health [1][3] - The children's market for lutein products has become a competitive battleground, driven by rising concerns among parents regarding children's vision health [1][15] Market Overview - The domestic market for lutein is estimated to reach nearly 6 billion yuan, with a compound annual growth rate (CAGR) of 19.8% from 2020 to 2024, significantly outpacing global market growth [4][3] - The eye care sector is the primary contributor to market growth, with annual sales of lutein soft capsules exceeding 200 million bottles [4] Competitive Landscape - The lutein market is characterized by intense competition across both health food and regular food sectors, with no dominant brand currently leading the market [2][20] - Major players in the extraction and processing segment include Chenguang Biotech, DSM, and Kemin, creating a "three-legged" competitive structure [4] Product Development - The market has seen a rapid increase in the registration of lutein health products, with over 150 products registered, primarily in capsule form [7][8] - Innovative product forms such as gummies and ready-to-drink beverages are gaining popularity, with the market for lutein gummies expected to exceed 1.5 billion yuan by 2024 [11] Consumer Trends - The demand for lutein products is driven by the rising incidence of myopia among children, with the overall myopia rate in Chinese children reaching 51.9% [18] - The average price of imported lutein products is significantly higher than that of domestic products, with imported items often exceeding 100 yuan per unit [17] Regulatory Environment - Lutein products are primarily classified as health foods and must undergo a registration process, as they are not included in the approved health food ingredient directory [9][14] - The lack of a clear definition for dietary supplements in China has led to many imported lutein products being marketed as regular foods, despite their health claims [13] Future Outlook - The lutein market is expected to continue evolving, with a focus on product differentiation and innovation to address the challenges of market saturation and consumer trust [20][22] - Companies are encouraged to invest in research and development to create unique products that can withstand competition and avoid the pitfalls of market homogenization [22]

关于使用部分闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300138 证券简称：晨光生物 公告编号：2025—069 晨光生物科技集团股份有限公司 晨光生物科技集团股份有限公司（以下简称"公司"）于 2023 年 9 月 21 日召开的第五届董事会第三次会议、第五届监事会第三次会议审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》。同意公司使用不超过 2 亿元暂时 闲置募集资金进行现金管理，用于购买安全性高、流动性好的理财产品/结构性 存款产品等，期限为自董事会审议通过之日起不超过 12 个月（详细内容请见 2023 年 9 月 22 日披露于巨潮资讯网的相关公告文件）。 2024 年 8 月 25 日，公司召开的第五届董事会第十二次会议、第五届监事会 第十一次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议 案》，同意公司使用不超过 1.6 亿元暂时闲置募集资金进行现金管理，用于购买 安全性高、流动性好的理财产品/结构性存款产品等，期限为自本次董事会审议 通过之日起不超过 12 个月（ ...